Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04848974 · ClinicalTrials.gov registry record · Phase 1
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT04848974: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT04848974 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04848974, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute myeloid leukemia. Chemotherapy drugs, such as uproleselan, cladribine, and low dose cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- DRUG Cladribine
- DRUG Cytarabine
- DRUG Uproleselan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04848974
The ClinicalTrials.gov registry entry for NCT04848974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cladribine is the first listed.
NCT04848974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04848974 about?
NCT04848974 is a clinical study titled "Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia". This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute myeloid leukemia. Chemotherapy drugs, such as uproleselan, cladribine, and low dose cytarabine, work in differe...
What is the current status of trial NCT04848974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2021-06-11. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT04848974?
The interventions under investigation include: Cladribine (DRUG), Cytarabine (DRUG), Uproleselan (DRUG).
Who is sponsoring clinical trial NCT04848974?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.